A biomarker analysis of plasma and tumor DNA in afatinib-treatedpatients with EGFR mutation-positive advanced adenocarcinoma of the lung.

Not Applicable

• Conditions: adenocarcinoma of the lung

• Registration Number: JPRN-UMIN000013806
• Lead Sponsor: Clinical Research Support Center Kyushu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-05-07
• Study Completion: 2017-11-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with active double cancer 2)Patients with interstitial pneumonia confirmed by chest CT. 3)Patient with neurologic symptom caused by non-treated brain metastasis 4) Patients with either superior vena cava syndrome, pericardial effusion, pleural effusion or ascites >= Grade 3. 5) Patients with an operation with the systemic anesthesia within 28 days before enrollment. 6)Patient with a palliative radiotherapy for the metastatic focus except the chest (including gamma knife treatment for the brain metastatic focus) within 7 days before enrollment (the irradiation of the same day 2 weeks ago is permitted as enrollment day as day0). 7) Patient with a radiation exposure to the chest or mediastinum within 14 days before enrollment (the irradiation of the same day 2 weeks ago is permitted as enrollment day as day0). 8)Patients with complication with mental disease or a mind symptom, and are judged to have difficulty in participation in the study. 9) Patient with positive HBs antigen. 10) Patient having a serious infection to need systemic treatment. 11)Any other patients who are regarded as unsuitable for this study by the investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified